Novartis said on Wednesday its Myfortic transplant rejection treatment improved quality of life for kidney transplant patients switching to the drug from conventional treatments.Novartis said a study showed that 66 percent of patients who suffered gastrointestinal complaints while on a conventional drug after surgery reported an improvement in their symptoms when they switched to Myfortic.
